| Product Name | GS-441524 |
| Expiry Date | 1 Year From The Date Of Manufacture |
| Storage Condition | Room Temperature |
| CAS | 1191237-69-0 |
| Function | Treatment For Cat FIP |
| Dosage Form | Injection |
| Country of Manufacture | China |
| Packaging | 6ml/vial, 8ml/vial, 10ml/vial |
| Strength | 20mg and 30mg |
GS-441524 is a nucleoside analog, which acts as an alternative substrate and RNA-chain terminator for the viral RNA dependent RNA polymerase. In simpler terms, it interjects itself in the chain reaction and prevents the replication of the virus. This action stops the spread of the virus to other cells, thereby enabling the immune system to build a complete immune response. It is a main metabolite of the antiviral prodrug remdesivir, and has a half-life of 24 hours in human patients.
In animals, GS-441524 and remdesivir were both found to be effective against feline coronavirus strains responsible for feline infectious peritonitis (FIP). FIP is a severe systemic disease that affects domestic cats. Cats with a healthy and active immune system will generally be able to fight off an infection or virus with the help of their white blood cells. However, cats with FIP usually have an immune defect or deficiency that causes the white blood cells to replicate the virus instead of fighting it off. This can lead to either wet FIP (no immune response) or dry FIP (partial immune response).
Feline Infectious Peritonitis (FIP) is a serious, often fatal disease affecting cats, caused by a mutation of the feline coronavirus. While most cats infected with the coronavirus experience mild or no symptoms, in some cases the virus mutates and triggers an abnormal immune response leading to FIP.
FIP primarily affects young cats and those with weakened immune systems. It manifests in two main forms: the “wet” (effusive) form, characterized by fluid accumulation in the abdomen or chest, and the “dry” (non-effusive) form, involving granulomas or inflammation in various organs. Common symptoms include fever, weight loss, lethargy, loss of appetite, and difficulty breathing.
Diagnosing FIP is challenging because symptoms can mimic other illnesses. Historically, FIP was considered untreatable and almost always fatal. However, recent advances in antiviral therapies, such as GS-441524, have shown promising results in improving survival and quality of life for affected cats.
Early diagnosis and appropriate treatment are crucial for managing FIP. Cat owners should seek veterinary advice promptly if their cat shows signs of illness, especially if young or immunocompromised. With proper care, many cats can achieve remission and extended survival.
GS-441524 is an antiviral drug that has shown promise in the treatment of feline infectious peritonitis (FIP), a viral disease caused by certain strains of feline coronavirus. As of my last update, GS-441524 is primarily used off-label in cats with FIP.
The dosage of GS-441524 injection for cats with FIP can vary depending on factors such as the cat's weight, the severity of the disease, and the veterinarian's assessment. Dosage regimens may also vary based on individual response and the specific formulation of GS-441524 being used.
Recommended dosage:
FIP(Wet): 0.3ml/kg * body weight kg + 0.1ml residue
FIP (Dry): 0.4ml/kg * body weight kg + 0.1ml residue
Eye / nerve entry: 0.5ml/kg * body weight kg + 0.1ml residue
Recurrence: 0.6 ml / kg * body weight kg + 0.1ml residue
